Compare Cytokinetics Inc (CYTK) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Halliburton Company — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Halliburton Company trades at $32.66 (market cap $27.14B). The key difference: Halliburton Company is far larger — about 3.1× Cytokinetics Inc's market cap, and Halliburton Company pays a 2.09% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Halliburton Company for 89 Days on average.
| CYTK | HAL | |
|---|---|---|
Market Cap | $8.62B | $27.14B |
Volume | 2,594,626 | 11,258,156 |
Sector | Health | Energy |
52-Week High | $87.26 | $42.98 |
52-Week Low | $54.76 | $21.82 |
Typical Hold Time | 19 Days | 89 Days |
Enterprise Value | $8.72B | $33.29B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Halliburton (HAL) trades at $31.75, down 2.96% on the day, with technical indicators showing bearish momentum. The stock has demonstrated consistent earnings beats in recent quarters and maintains solid profitability metrics including 7.16% net margin and 14.89% ROE. Recent developments include expansion into Venezuela through partnerships with Eneva and WESCA, along with a major contract win for Cyprus' Cronos gas project, positioning the company for international growth opportunities.
Despite near-term technical weakness, Halliburton presents value with a 16.62 P/E ratio and strong analyst support (73% buy ratings) targeting $43.11 consensus. Risks include oil price volatility and execution challenges in new international markets, but the company's diversified service portfolio and improving cash flow trends support long-term growth prospects in the energy services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
